Cannabinoid actives

Elevate patient health and convenience

Ready to unlock the full potential of cannabinoid-based therapies? As an end-to-end partner, we can help enhance the odds of therapeutic breakthroughs and streamline development pathways in the cannabinoids space.

We offer a unique innovation platform powered by our leading-edge technical capabilities, clinical study proficiency, and robust cannabidiol (CBD) API offering elevated by Verilege™. This suite of expert services and superior customer care is designed to help you navigate the market with confidence and peace of mind.

Together, we can unlock new treatment possibilities for patients worldwide.

Transform patient care with CBtru®

CBtru® is an innovative, formulated CBD drug product intermediate and patent-pending solution that is designed to overcome bioavailability challenges, optimizing patient convenience and compliance.

Offering comparable bioavailability to the only market-approved CBD drug product (which is in a liquid oil-based form), CBtru® enables the development of oral solid dosage forms with higher API loading. This innovative solution is making more patient-friendly therapies—such as capsules, tablets, and more—possible in the CBD space.

Discover more

Due diligence considerations in drug development

Cannabinoid-based innovation may be complex, but it doesn’t need to be. Discover strategies to succeed at each step of drug discovery and development—from choosing the right API to fine-tuning patient experience.

Download whitepaper

Webinars

Best practices in CBD research and development

CBD and other cannabinoids hold great therapeutic promise. But currently available drug delivery formats face challenges, like API absorption. Learn how to optimize CBD bioavailability.

Watch webinar

The future of cannabinoid research and development

What’s next in cannabinoid-based R&D and product innovation? Find out in this on-demand Future Scientific Horizons panel discussion from ICBC Berlin 2024.

Watch webinar

Must-know insights on CBD for pharma

What’s the difference between naturally sourced and synthetic cannabinoids? Or why is bioavailability a key consideration? Get the answers to common questions and bust misconceptions about CBD for pharma applications.

Explore FAQs

Ready to step confidently into cannabinoid research and development?

Let’s enter the pharma cannabinoids market with high-quality, science-backed products that meet patient needs and regulatory standards.

Partner with us

dsm-firmenich’s API portfolio elevated by Verilege™

Simplify the drug approvals process with Verilege™, an expert services platform offering regulatory, quality, sustainability, and supply chain support for APIs.

Read more
Introducing dsm-firmenich’s new portfolio of taste solutions for pharmaceutical formulations

Discover our novel portfolio offering for the pharmaceutical market, which aims to address a growing need for full-service flavor solutions and taste modulation strategies.

Read more
New CBD bioavailability study with CBtru®

New study confirms CBtru®, a novel CBD drug product intermediate, demonstrates equal bioavailability to leading oil-based CBD drug product.

Read more

References

Ożarowski, M., Karpiński, T. M., Zielińska, A., Souto, E. B., & Wielgus, K. (2021). Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action. International journal of molecular sciences, 22(9), 4294. https://doi.org/10.3390/ijms22094294
Argueta, D. A., Ventura, C. M., Kiven, S., Sagi, V., & Gupta, K. (2020). A Balanced Approach for Cannabidiol Use in Chronic Pain. Frontiers in pharmacology, 11, 561. https://doi.org/10.3389/fphar.2020.00561
O'Brien K. (2022). Cannabidiol (CBD) in Cancer Management. Cancers, 14(4), 885. https://doi.org/10.3390/cancers14040885